Press Releases August 7, 2026 04:01 PM

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

Kiniksa Pharmaceuticals to Host Fireside Chat at Canaccord Genuity Annual Growth Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
KNSA

Kiniksa Pharmaceuticals International, plc announced that its management team will present at the Canaccord Genuity 46th Annual Growth Conference via a fireside chat, available live and via replay on the company's website. Kiniksa focuses on developing novel therapies primarily for cardiovascular diseases and other debilitating conditions with unmet medical needs.

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
KNSA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kiniksa management to present at a prominent investor conference, increasing investor engagement.
  • The presentation will be available live and on replay, broadening access to investors and analysts.
  • Kiniksa's strategic focus is on biopharmaceutical innovations targeting cardiovascular diseases, leveraging biologic rationale and validated mechanisms.

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
[email protected]


Risks

  • The impact of the presentation on investor sentiment may be limited if new data or updates are not disclosed, creating uncertainty.
  • Kiniksa’s success is contingent on the development and commercialization of novel therapies, which inherently carries regulatory and clinical trial risks.
  • Market conditions and competitive pressures in the biopharmaceutical sector could affect the company’s growth prospects and stock performance.

More from Press Releases

Critical Metals Corp. Merger with European Lithium Advances to Shareholder Vote Following Court Ruling Sep 15, 2026 XTEND Expands Global Footprint with New Site in Mexico as Mexico Allocates $17.5 Billion to Defense and Security in 2026¹ Sep 15, 2026 Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics Sep 15, 2026 Safe Harbor to Address Banking and Capital Access for Colorado Cannabis Operators at IgniteIt Market Spotlight 2026 Sep 15, 2026 PolyPid Announces Participation in Upcoming Fall Investor Conferences Sep 15, 2026